Sympathetic α2-adrenoceptors prevent cardiac hypertrophy and fibrosis in mice at baseline but not after chronic pressure overload

Cardiovascular Research

Volumn 86, Issue 3, 2010, Pages 432-442

  Gilsbach, Ralf ^a   Schneider, Johanna ^a   Lother, Achim ^a   Schickinger, Stefanie ^b   Leemhuis, Jost ^a   Hein, Lutz ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

^b UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

Adrenoceptors; Cardiac hypertrophy; Norepinephrine; Pressure overload; Transgenic mouse model

Indexed keywords

ALPHA 2A ADRENERGIC RECEPTOR; ALPHA 2C ADRENERGIC RECEPTOR; COCAINE AND AMPHETAMINE REGULATED TRANSCRIPT PEPTIDE; DOPAMINE BETA MONOOXYGENASE; GALANIN; MEDETOMIDINE; NEUROPEPTIDE Y; NORADRENALIN; SOMATOSTATIN; TRANSCRIPTOME; TRITIUM;

ADRENERGIC ACTIVITY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA CONSTRICTION; ARTICLE; BRADYCARDIA; CONTROLLED STUDY; DESENSITIZATION; DOSE RESPONSE; ENDOCYTOSIS; FEEDBACK SYSTEM; GENE DELETION; GENE EXPRESSION; HEART ATRIUM; HEART DISEASE; HEART HYPERTROPHY; HEART MUSCLE FIBROSIS; HEART VENTRICLE OVERLOAD; HYPOTENSION; LOW DRUG DOSE; MOUSE; NEURITE; NONHUMAN; NORADRENALIN BLOOD LEVEL; NORADRENALIN RELEASE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; STELLATE GANGLION; SYMPATHETIC FUNCTION; SYMPATHETIC GANGLION; SYMPATHETIC NERVE CELL; TRANSGENE; WILD TYPE;

ADRENERGIC ALPHA-AGONISTS; ANIMALS; BLOOD PRESSURE; CARDIOMEGALY; CELLS, CULTURED; DISEASE MODELS, ANIMAL; DOPAMINE BETA-HYDROXYLASE; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOCYTOSIS; FEEDBACK, PHYSIOLOGICAL; FIBROSIS; GENE EXPRESSION PROFILING; HEART; HEART RATE; HUMANS; HYPERTENSION; MEDETOMIDINE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICE, TRANSGENIC; MYOCARDIUM; NEURITES; NOREPINEPHRINE; PROMOTER REGIONS, GENETIC; RECEPTORS, ADRENERGIC, ALPHA-2; RNA, MESSENGER; SYMPATHETIC FIBERS, POSTGANGLIONIC; SYMPATHETIC NERVOUS SYSTEM;

EID: 77952333999     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvq014     Document Type: Article

References (39)

1. Bylund DB, Eikenberg DC, Hieble JP, Langer SZ, Lefkowitz RJ, Minneman KP et al. International Union of Pharmacology nomenclature of adrenoceptors. Pharmacol Rev 1994;46:121-136.
2. Starke K. Presynaptic autoreceptors in the third decade: focus on alpha2-adrenocep-tors. J Neurochem 2001;78:685-693.
3. Gilsbach R, Hein L. Presynaptic metabotropic receptors for acetylcholine and adrena-line/noradrenaline. Handb Exp Pharmacol 2008;184:261-288.
4. Link RE, Desai K, Hein L, Stevens ME, Chruscinski A, Bernstein D et al. Cardiovascular regulation in mice lacking alpha2-adrenergic receptor subtypes b and c. Science 1996; 273:803-805.
5. Philipp M, Brede ME, Hadamek K, Gessler M, Lohse MJ, Hein L. Placental alpha(2)-adrenoceptors control vascular development at the interface between mother and embryo. Nat Genet 2002;31:311-315.
6. Brede M, Nagy G, Philipp M, Sorensen JB, Lohse MJ, Hein L. Differential control of adrenal and sympathetic catecholamine release by alpha 2-adrenoceptor subtypes. Mol Endocrinol 2003;17:1640-1646.
7. Lymperopoulos A, Rengo G, Funakoshi H, Eckhart AD, Koch WJ. Adrenal GRK2 upregulation mediates sympathetic overdrive in heart failure. Nat Med 2007;13: 315-323.
8. MacMillan LB, Hein L, Smith MS, Piascik MT, Limbird LE. Central hypotensive effects of the alpha2a-adrenergic receptor subtype. Science 1996;273:801-803.
9. 2a-adrenergic receptor via 'hit and run' gene targeting reveals the role of this subtype in sedative, analgesic, and anesthetic-sparing responses in vivo. Proc Natl Acad Sci USA 1997;94:9950-9955.
10. Wang M, Ramos BP, Paspalas CD, Shu Y, Simen A, Duque A et al. Alpha2A-adrenoceptors strengthen working memory networks by inhibiting cAMP-HCN channel signaling in prefrontal cortex. Cell 2007;129:397-410.
11. Altman JD, Trendelenburg AU, MacMillan L, Bernstein D, Limbird L, Starke K et al. Abnormal regulation of the sympathetic nervous system in alpha2A-adrenergic receptor knockout mice. Mol Pharmacol 1999;56:154-161.
12. Bucheler M, Hadamek K, Hein L. Two alpha2-adrenergic receptor subtypes, alpha2A and alpha2C, inhibit transmitter release in the brain of gene-targeted mice. Neuro-science 2002;109:819-826.
13. Olli-Lahdesmaki T, Kallio J, Scheinin M. Receptor subtype-induced targeting and subtype-specific internalization of human alpha(2)-adrenoceptors in PC12 cells. J Neurosci 1999;19:9281-9288.
14. Brede M, Wiesmann F, Jahns R, Hadamek K, Arnolt C, Neubauer S et al. Feedback inhibition of catecholamine release by two different alpha2-adrenoceptor subtypes prevents progression of heart failure. Circulation 2002;106:2491-2496.
15. Perrino C, Rockman HA. Reversal of cardiac remodeling by modulation of adrenergic receptors: a new frontier in heart failure. Curr Opin Cardiol 2007;22:443-449.
16. Cohn J. Sympathetic nervous system in heart failure. Circulation 2002;106:2417-2418.
17. Gilsbach R, Roser C, Beetz N, Brede M, Hadamek K, Haubold M et al. Genetic dissection of alpha2-adrenoceptor functions in adrenergic versus nonadrenergic cells. Mol Pharmacol 2009;75:1160-1170.
18. Daunt DA, Hurt C, Hein L, Kallio J, Feng F, Kobilka BK Subtype-specific intracellular trafficking of alpha2-adrenergic receptors. Mol Pharmacol 1997;51:711-720.
19. Hein L, Altman JD, Kobilka BK. Two functionally distinct alpha2-adrenergic receptors regulate sympathetic neurotransmission. Nature 1999;402:181-184.
20. Beetz N, Hein L, Meszaros J, Gilsbach R, Barreto F, Meissner M et al. Transgenic simulation of human heart failure-like L-type Ca2+-channels: implications for fibrosis and heart rate in mice. Cardiovasc Res 2009;84:396-406.
21. Kawahara Y, Tanonaka K, Daicho T, Nawa M, Oikawa R, Nasa Y et al. Preferable anesthetic conditions for echocardiographic determination of murine cardiac function. J Pharmacol Sci 2005;99:95-104.
22. Gilsbach R, Brede M, Beetz N, Moura E, Muthig V, Gerstner C et al. Heterozygous alpha 2C-adrenoceptor-deficient mice develop heart failure after transverse aortic constriction. Cardiovasc Res 2007;75:728-737.
23. Hein L, Ishii K, Coughlin SR, Kobilka BK. Intracellular targeting and trafficking of thrombin receptors. A novel mechanism for resensitization of a G protein-coupled receptor. J Biol Chem 1994;269:27719-27726.
24. Muthig V, Gilsbach R, Haubold M, Philipp M, Ivacevic T, Gessler M et al. Upregulation of soluble vascular endothelial growth factor receptor 1 contributes to angiogenesis defects in the placenta of alpha 2B-adrenoceptor deficient mice. Circ Res 2007;101: 682-691.
25. Trendelenburg AU, Philipp M, Meyer A, Klebroff W, Hein L, Starke K. All three alpha2-adrenoceptor types serve as autoreceptors in postganglionic sympathetic neurons. Naunyn Schmiedebergs Arch Pharmacol 2003;368:504-512.
26. Small KM, Brown KM, Seman CA, Theiss CT, Liggett SB. Complex haplotypes derived from noncoding polymorphisms of the intronless {alpha}2A-adrenergic gene diversify receptor expression. Proc Natl Acad Sci USA 2006;103:5472-5477.
27. Small KM, Forbes SL, Brown KM, Liggett SB. An asn to lys polymorphism in the third intracellular loop of the human alpha 2A-adrenergic receptor imparts enhanced agonist-promoted Gi coupling. J Biol Chem 2000;275:38518-38523.
28. Sober S, Org E, Kepp K, Juhanson P, Eyheramendy S, Gieger C et al. Targeting 160 candidate genes for blood pressure regulation with a genome-wide genotyping array. PLoS One 2009;4:e6034.
29. Kurnik D, Muszkat M, Li C, Sofowora GG, Solus J, Xie HG et al. Variations in the alpha2A-adrenergic receptor gene and their functional effects. Clin Pharmacol Ther 2006;79:173-185.
30. Lu R, Li Y, Zhang Y, Chen Y, Shields AD, Winder DG et al. Epitope-tagged receptor knock-in mice reveal that differential desensitization of alpha2-adrenergic responses is because of ligand-selective internalization. J Biol Chem 2009;284:13233-13243.
31. Eason MG, Liggett SB. Subtype-selective desensitization of alpha 2-adrenergic receptors. Different mechanisms control short and long term agonist-promoted desensitization of alpha 2C10, alpha 2C4, and alpha 2C2.J Biol Chem 1992;267:25473-25479.
32. Wang Q, Limbird LE. Regulation of alpha2AR trafficking and signaling by interacting proteins. Biochem Pharmacol 2007;73:1135-1145.
33. Guyenet PG. The sympathetic control of blood pressure. Nat Rev Neurosci 2006;7: 335-346.
34. Salazar NC, Chen J, Rockman HA. Cardiac GPCRs: GPCR signaling in healthy and failing hearts. Biochim Biophys Acta 2007;1768:1006-1018.
35. Cohn JN, Pfeffer MA, Rouleau J, Sharpe N, Swedberg K, Straub M et al. Adverse mortality effect of central sympathetic inhibition with sustained-release moxonidine in patients with heart failure (MOXCON). Eur J Heart Fail 2003;5:659-667.
36. TankJ, Diedrich A, Szczech E, Luft FC, Jordan J. Alpha-2 adrenergic transmission and human baroreflex regulation. Hypertension 2004;43:1035-1041.
37. TankJ, Jordan J, Diedrich A, Obst M, Plehm R, Luft FC et al. Clonidine improves spontaneous baroreflex sensitivity in conscious mice through parasympathetic activation. Hypertension 2004;43:1042-1047.
38. Aggarwal A, Esler MD, Socratous F, Kaye DM. Evidence for functional presynaptic alpha-2 adrenoceptors and their down-regulation in human heart failure. J Am Coll Cardiol 2001;37:1246-1251.
39. Lang CC, Stein CM, Nelson RA, He HB, Belas FJ, Blair IA et al. Sympathoinhibitory response to clonidine is blunted in patients with heart failure. Hypertension 1997; 30:392-397.